Current issues in breast cancer

Current issues highlight some of the latest research into breast cancer, new therapies becoming available and new drug treatments coming to the market.

Aromatase inhibitors may be better than Tamoxifen In Er+, Her-2 + breast cancer in post-menopausal breast cancer A recent multi-centre trial reported in the Journal of Clinical Oncology (Vol 19: 3808-3816) reported a superior response rate in post menopausal breast cancer patients who were treated with the...
Combined Tamoxifen and Ovarian Ablation (by Lhrh Agonist) beats ovarian ablation alone in young women presenting with advanced b Dr Kiljn and colleagues from the European Organisation for Research and Treatment of Cancer recently reported an overview of four trials examining the combination of tamoxifen and ovarian 'functional...
Oestrogen Receptor Expression, usefulness of Tamoxifen and Gene Expression Profiles in hereditary breast cancer There are two well established hereditary breast cancer genes that have now been well worked out: BRCA 1 and BRCA 2, inheritance of which strongly correlates with an increased lifetime risk of breast...
Breast conserving surgery and Brca-linked breast cancer A study from Sloan Kettering Memorial Hospital, New York and presented at the 23rd Annual San Antonio Breast Cancer Symposium demonstrated a 13% relapse risk in the breast after breast conserving...
Humanised Monoclonal Antibody against Her-2 receptor in breast cancer therapy HER-2, a cellular receptor for epidermal growth factor, is a unique therapeutic target in breast cancer. In approximately 25% of cases, breast cancer cells over-express/amplify HER-2. Women with such...
Capecitabine plus Taxotere in metastatic breast cancer At the 23rd San Antonio Breast cancer symposium, data were presented that showed that the addition of capecitabine to docetaxel/taxotere (one of the taxane group of cytotoxic chemotherapy agents that...
Taxol plus Adriamycin chemotherapy A multicentre European trial's findings add to those of accumulating American data that the combination of Taxol and adriamycin (doxorubicin) chemotherapy is superior to standard FAC/FEC chemotherapy...
The effect of age on overall prognosis for breast cancer a population based study + implications for therapy Although by no means the first study to report on the influence of age at presentation of breast cancer on prognosis, the recent report and editorial in the British Medical Journal on this subject...
Herceptin plus chemotherapy The addition of Herceptin to standard chemotherapy in patients with HER-2 expressing metastatic breast cancer increases the response rate over the standard chemotherapy alone.
Adjuvant Systemic (i.e. Chemo Or Hormonal) therapy for small primary breast cancer patients A recent sub-group analysis of patients in NSABP (the American: National Surgical Adjuvant Breast Project) trials, and all with primary breast cancers smaller than 1 cm in diameter, has recently been...

Page: [1] [2] [3]

[ « Previous | Next » ]